Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Bracci

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
European Journal of Immunology|June 23, 2009
Type I IFN regulate DC turnover in vivoFabrizio Mattei, Laura Bracci, David F Tough, et al.
Seminars in Immunopathology|May 26, 2011
Immunomodulatory effects of cyclophosphamide and implementations for vaccine designAntonella Sistigu, Sophie Viaud, Nathalie Chaput, et al.
Journal of Cell Science|June 15, 2007
Ca2+ signaling through ryanodine receptor 1 enhances maturation and activation of human dendritic cellsLaura Bracci, Mirko Vukcevic, Giulio Spagnoli, et al.
Expert Opinion on Biological Therapy|October 20, 2006
Clinical applications of virosomes in cancer immunotherapyMichel Adamina, Ulrich Guller, Laura Bracci, et al.
Cytokine & Growth Factor Reviews|December 27, 2021
Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19Eleonora Aricò, Laura Bracci, Luciano Castiello, et al.
Methods in Cell Biology|October 17, 2025
Isolation and phenotype analysis of tissue-resident lymphocytes from mouse colonAlessia Fiore, Michela Tozzi, Paola Rinzo, et al.
Vaccine|July 11, 2006
Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virusLaura Bracci, Irene Canini, Massimo Venditti, et al.
Vaccine|April 7, 2005
Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal levelLaura Bracci, Irene Canini, Simona Puzelli, et al.
Trends in Molecular Medicine|September 12, 2006
MHC-peptide specificity and T-cell epitope mapping: where immunotherapy startsMaurizio Provenzano, Monica C Panelli, Simone Mocellin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2011
Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-primingSilvia Lorenzi, Fabrizio Mattei, Antonella Sistigu, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
European Journal of Immunology|June 23, 2009
Type I IFN regulate DC turnover in vivoFabrizio Mattei, Laura Bracci, David F Tough, et al.
Seminars in Immunopathology|May 26, 2011
Immunomodulatory effects of cyclophosphamide and implementations for vaccine designAntonella Sistigu, Sophie Viaud, Nathalie Chaput, et al.
Journal of Cell Science|June 15, 2007
Ca2+ signaling through ryanodine receptor 1 enhances maturation and activation of human dendritic cellsLaura Bracci, Mirko Vukcevic, Giulio Spagnoli, et al.
Expert Opinion on Biological Therapy|October 20, 2006
Clinical applications of virosomes in cancer immunotherapyMichel Adamina, Ulrich Guller, Laura Bracci, et al.
Cytokine & Growth Factor Reviews|December 27, 2021
Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19Eleonora Aricò, Laura Bracci, Luciano Castiello, et al.
Methods in Cell Biology|October 17, 2025
Isolation and phenotype analysis of tissue-resident lymphocytes from mouse colonAlessia Fiore, Michela Tozzi, Paola Rinzo, et al.
Vaccine|July 11, 2006
Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virusLaura Bracci, Irene Canini, Massimo Venditti, et al.
Vaccine|April 7, 2005
Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal levelLaura Bracci, Irene Canini, Simona Puzelli, et al.
Trends in Molecular Medicine|September 12, 2006
MHC-peptide specificity and T-cell epitope mapping: where immunotherapy startsMaurizio Provenzano, Monica C Panelli, Simone Mocellin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2011
Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-primingSilvia Lorenzi, Fabrizio Mattei, Antonella Sistigu, et al.
Pageof 4